Astellas Pharma ((ALPMF)), Astellas Pharma ((ALPMY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Study Overview: Astellas Pharma is conducting a post-marketing surveillance study titled ‘Japan Post-Marketing Surveillance – Specified Drug Use-results Survey for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis.’ The study aims to evaluate the safety and effectiveness of peficitinib in real-world clinical settings for patients with rheumatoid arthritis, as part of a mandatory surveillance requested by the Pharmaceuticals and Medical Devices Agency in Japan.
Intervention/Treatment: The study focuses on the drug peficitinib, an oral medication administered once daily after meals, intended to treat rheumatoid arthritis by assessing its safety and effectiveness in everyday clinical practice.
Study Design: This is an observational cohort study with a prospective time perspective. There is no allocation or intervention model specified, and the primary purpose is to monitor the drug’s performance in a real-world setting without any masking.
Study Timeline: The study began on September 2, 2019, and is currently recruiting participants. The last update was submitted on July 10, 2025, indicating ongoing data collection and analysis.
Market Implications: The ongoing study could influence Astellas Pharma’s stock performance by providing insights into peficitinib’s real-world effectiveness and safety, potentially boosting investor confidence. As the rheumatoid arthritis treatment market is competitive, positive results could enhance Astellas’s position against competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.